Roche: leukaemia drug benefits patients in phase III study
(CercleFinance.com) - Patients with chronic lymphocytic leukaemia who received Venclexta/Venclyxto plus MabThera/Rituxan lived significantly longer without their disease worsening, Roche said on Tuesday.
The Swiss drugmaker said phase III data showed that the chemotherapy-free combination reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia.
At two years, 84.9% of patients in the Venclexta/Venclyxto plus MabThera/Rituxan arm had not experienced disease progression, compared to 36.3% of patients in the control arm receiving bendamustine.
The study included 389 patients who had previously been treated with at least one, but not more than three lines of therapy.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The Swiss drugmaker said phase III data showed that the chemotherapy-free combination reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia.
At two years, 84.9% of patients in the Venclexta/Venclyxto plus MabThera/Rituxan arm had not experienced disease progression, compared to 36.3% of patients in the control arm receiving bendamustine.
The study included 389 patients who had previously been treated with at least one, but not more than three lines of therapy.
Copyright (c) 2017 CercleFinance.com. All rights reserved.